HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and increased the price target from $48 to $50.
February 21, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics' Buy rating is maintained by HC Wainwright & Co., with the price target raised from $48 to $50.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock from the analyst's perspective. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100